Information  X 
Enter a valid email address

Revenue, cash up for Oxford Biometrica as work starts on COVID-19 vaccine

By BFN News | 07:35 AM | Thursday 17 September, 2020

Biotech company Oxford Biomedica increased its revenue in the first half of 2020 by 6%, it announced this morning. Bioprocessing and commercial development were particularly strong, posting revenues of £23.4m, up by 24%. The company recorded an operating loss of £5.8m for the first six months of the year, down from £6.1m in the first half of 2019. After a fundraising round, the group now has more than £50m in cash on its balance sheet. CEO John Dawson highlighted Oxford Biometrica's work with AstraZeneca, with which it has signed a three-year deal for large-scale manufacturing of a potential vaccine for COVID-19. Story provided by

a d v e r t i s e m e n t